| Literature DB >> 35333545 |
Charis E Teh1,2, Simon P Preston1,2, Alissa K Robbins1,2, Michael D Stutz1,2, James Cooney1,2, Michelle P Clark1,2, Antonia N Policheni1,2, Cody C Allison1,2, Liana Mackiewicz1, Philip Arandjelovic1,2, Gregor Ebert1,2, Marcel Doerflinger1,2, Tania Tan1, Lucille C Rankin1,2, Peggy P Teh1,2,3,4, Gabrielle T Belz1,2, Axel Kallies1,5, Andreas Strasser1,2, Marc Pellegrini1,2, Daniel H D Gray1,2.
Abstract
Targeting the potent immunosuppressive properties of FOXP3+ regulatory T cells (Tregs) has substantial therapeutic potential for treating autoimmune and inflammatory diseases. Yet, the molecular mechanisms controlling Treg homeostasis, particularly during inflammation, remain unclear. We report that caspase-8 is a central regulator of Treg homeostasis in a context-specific manner that is decisive during immune responses. In mouse genetic models, targeting caspase-8 in Tregs led to accumulation of effector Tregs resistant to apoptotic cell death. Conversely, inflammation induced the MLKL-dependent necroptosis of caspase-8-deficient lymphoid and tissue Tregs, which enhanced immunity to a variety of chronic infections to promote clearance of viral or parasitic pathogens. However, improved immunity came at the risk of lethal inflammation in overwhelming infections. Caspase-8 inhibition using a clinical-stage compound revealed that human Tregs have heightened sensitivity to necroptosis compared with conventional T cells. These findings reveal a fundamental mechanism in Tregs that could be targeted to manipulate the balance between immune tolerance versus response for therapeutic benefit.Entities:
Mesh:
Substances:
Year: 2022 PMID: 35333545 DOI: 10.1126/sciimmunol.abn8041
Source DB: PubMed Journal: Sci Immunol ISSN: 2470-9468